301 filings
Page 6 of 16
8-K
0kxabd2h4z0ski
8 May 20
Regulation FD Disclosure
7:00am
8-K
icn qkvjd1j
4 May 20
Entry into a Material Definitive Agreement
7:00am
8-K
c8332hzdlqr hxdggok
15 Apr 20
Other Events
6:31am
8-K
7pmhy
13 Mar 20
Regulation FD Disclosure
5:00pm
8-K
50sdfmw7d
7 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
vj4o5f
4 Dec 19
Regulation FD Disclosure
9:02am
8-K
tumuq3jxxbyjw4 91
2 Dec 19
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 In Oral Mucositis
8:59am
8-K
radjtaqk9vgb
22 Oct 19
Oragenics, Inc. to Present at the Bio Investor Forum
8:33am
8-K
le7wdbryt26euoxrbg0u
30 Sep 19
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
8:07am
8-K
qi4y1ww
25 Sep 19
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013
8:53am
8-K
xl5l99hca9fwd8oygsey
23 Sep 19
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of
9:02am
8-K
79elyptlcn
6 Sep 19
Regulation FD Disclosure
5:20pm
8-K
qwu9xrr fzrf
21 Jun 19
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
5fa5e
25 Mar 19
Oragenics Announces Closing of $12.5 Million Underwritten Public Offering
4:32pm
8-K
h8vjptn
21 Mar 19
Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering
9:26am
8-K
wmmmq27k rta
20 Mar 19
Organics Announces Proposed Underwritten Public Offering
5:28pm
8-K
9z3 v7513swc4g6ir
15 Mar 19
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
4:40pm
8-K
ww4dbwmh96cuybahrvh
22 Feb 19
Departure of Directors or Certain Officers
5:01pm
8-K
aqki si4po
21 Dec 18
Departure of Directors or Certain Officers
4:27pm
8-K
xvnj10w wcr5725g
3 Dec 18
Regulation FD Disclosure
5:27pm